Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Current Neurology and Neuroscience Reports
|
July 2, 2008
Neuroprotection in Parkinson's disease: myth or reality?
Tiffini Voss, Bernard Ravina
Parkinsonism & Related Disorders
|
December 6, 2012
Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
Tiffini Voss, Daun Bahr, Jeffrey Cummings, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 17, 2011
Risk of surgical delivery to deep nuclei: a meta-analysis
Jonathan Kimmelman, Katherine Duckworth, Tim Ramsay, et al.
Journal of Alzheimer'S Disease Reports
|
August 9, 2021
Medications in Patients with Dementia and Behavioral Disturbance
Wenjun Zhong, Xinyue Liu, Tiffini Voss, et al.
Schizophrenia Research
|
June 8, 2024
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial
Yuki Mukai, Robert Lupinacci, Stephen Marder, et al.
Paediatric Anaesthesia
|
December 8, 2021
Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study
Tiffini Voss, Aobo Wang, Matthew DeAngelis, et al.
Journal of Alzheimer'S Disease : JAD
|
February 6, 2023
Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions
Tiffini Voss, James Kost, Swati Pal Mercer, et al.
Cephalalgia : an International Journal of Headache
|
June 9, 2016
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss, Richard B Lipton, David W Dodick, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 30, 2018
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
Tiffini Voss, Jerry Li, Jeffrey Cummings, et al.
Clinical and Translational Science
|
November 24, 2019
Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment
Chi-Chung Li, Tiffini Voss, Ken Kowalski, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Current Neurology and Neuroscience Reports
|
July 2, 2008
Neuroprotection in Parkinson's disease: myth or reality?
Tiffini Voss, Bernard Ravina
Parkinsonism & Related Disorders
|
December 6, 2012
Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
Tiffini Voss, Daun Bahr, Jeffrey Cummings, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 17, 2011
Risk of surgical delivery to deep nuclei: a meta-analysis
Jonathan Kimmelman, Katherine Duckworth, Tim Ramsay, et al.
Journal of Alzheimer'S Disease Reports
|
August 9, 2021
Medications in Patients with Dementia and Behavioral Disturbance
Wenjun Zhong, Xinyue Liu, Tiffini Voss, et al.
Schizophrenia Research
|
June 8, 2024
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial
Yuki Mukai, Robert Lupinacci, Stephen Marder, et al.
Paediatric Anaesthesia
|
December 8, 2021
Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study
Tiffini Voss, Aobo Wang, Matthew DeAngelis, et al.
Journal of Alzheimer'S Disease : JAD
|
February 6, 2023
Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions
Tiffini Voss, James Kost, Swati Pal Mercer, et al.
Cephalalgia : an International Journal of Headache
|
June 9, 2016
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss, Richard B Lipton, David W Dodick, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 30, 2018
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
Tiffini Voss, Jerry Li, Jeffrey Cummings, et al.
Clinical and Translational Science
|
November 24, 2019
Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment
Chi-Chung Li, Tiffini Voss, Ken Kowalski, et al.
Page
of 2